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Fig.　1　Clinical course of fever, WBC, esinocyte and medication.
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Table　1　Laboratory data on admission
WBC 4700 /μl AST 21 IU/l PT 12.7 S
Neut. 45.6 % ALT 11 IU/l PT 90 %
Lymp. 36.6 % ALP 149 IU/l PT-INR 1.06
Mono. 7.2 % γGTP 14 IU/l APTT 29.2 S
Eosi. 10.0 % LDH 187 IU/l Fib 337 mg/dl
Baso. 0.6 % T-Bil 0.40 IU/l HCV Ab (-)
RBC 304 × 104 /μl BUN 34.6 mg/dl HBs AG (-)
Ht 28.2 % Cre 2.02 mg/dl DLST
Hb 9.8 g/dl Na 140 mEq/l PZA 711 cpm
MCV 92.8 fl K 4.4 mEq/l S.I. 98 % (<180%: negative)
MCH 32.2 pg Cl 108 mEq/l SM 908 cpm
MCHC 34.8 g/dl TP 6.5 g/dl S.I. 488 % (>199%: positive)
Plt 11.1 × 104 /μl CRP 0.18 mg/dl
Dear Editor
A Case of Streptomycin-Induced
Pneumonitis
Antituberculosis drugs are associated with predict-
able incidences of adverse effects such as fever, skin
rash, and hepatitis.1 First-line agents such as isoni-
azid (INH), rifampicin (RFP), and ethambutol (EB)
are sometimes reported to cause drug induced pneu-
monitis.2 In contrast, although pyrazinamide (PZA)
and streptomycin (SM) have side effects including
hepatotoxicity and ototoxicity, respectively, 1 to our
knowledge, pneumonitis induced by these drugs has
not been reported.
We report a case of SM-induced pneumonitis diag-
nosed by the drug lymphocyte stimulation test
(DLST).
CASE REPORT
An 89-year-old man was admitted for abnormal lung
shadow. His chest radiograph showed consolidation
in the upper side of the right lung. Physical examina-
tion was unremarkable without fever and cough.
Laboratory data revealed anemia and thrombocy-
topenia with mild renal dysfunction (Table 1). Myco-
bacterium tuberculosis infection was confirmed by gas-
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Fig.　2a　Chest X-ray at onset of dyspnea showed bilateral 
spotty consolidation in the lungs.
Fig.　2b　Chest CT at onset of dyspnea indicated membra-
nous shadow with small reticulous shadow.
tric fluid culture and PCR. Sputum was not examined
as sample could not be obtained.
Antituberculosis drugs were started as follows,
INH (0.3 gday), RFP (0.45 gday), and EB (0.75 g
day). Because he developed skin rash with itching
and eosinophilia after two weeks, these drugs were
all ceased and symptoms improved within ten days.
Although INH and RFP were re-admitted without
side effects, after EB was re-started, skin eruption
with itching was seen again after a few days. There-
fore, EB was stopped. As its back up, PZA (1.0 gday)
and SM (0.5 g × 2 daysweek) were started. How-
ever, about a month after beginning these drugs, skin
eruption with itching was seen again and blood ex-
amination revealed eosinophilia (Fig. 1). Although we
stopped all drugs immediately, skin rash continued
for two weeks, and then the patients developed high
fever with dyspnea. Differential cell count of sputum
revealed 60% lymphocytes and 40% neutrophils. DLST
of SM was positive, but that of PZA was negative (Ta-
ble 1). Because chest X ray films showed bilateral
spotty consolidation (Fig. 2a) and chest CT indicated
membranous shadows, with small reticular shadows
which were consistent with a nonspecific interstitial
pneumonia (NSIP) pattern (Fig. 2b), we suspected
drug induced pneumonitis. Prednisolone ( 30 mg )
was administered orally. With this therapy, pneu-
monitis and skin rash improved in a short time and
eosinophilia returned to normal ranges rapidly. After
a while, we re-tried INH and RFP at a regular dose
because the susceptibility test of these two drugs for
tuberculosis was sensitive. Thereafter, the patient ex-
perienced no difficulties with these drugs.
DISCUSSION
Adverse drug reaction (ADR) is commonly explained
by pharmacological actions of a drug. However, ADR
occurs unpredictably as an idiosyncratic reaction in a
few patients.3 According to Suzuki et al. , the drug
provocation test (DPT), controlled administration of a
suspected drug,4 is recommended in order to diag-
nose antituberculosis drug induced hypersensitivity
reactions, because DPT for antituberculosis drugs
was more sensitive than DLST.5 In this case, EB was
confirmed to induce skin rash by DPT. The skin rash
was seen by re-exposure to EB and disappeared
when EB was stopped. However, concerning intersti-
tial pneumonia following additional medication by
PZA and SM, we did not try DPT or desensitizing
therapy because they may have induced a life-
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threatening side effect such as respiratory failure. In-
stead of DPT, we examined DLST for PZA and SM.
DLST is performed to examine the sensitivity of T
cells to a suspected drug by measuring the prolifera-
tion of the cells exposed to the drug in vitro. Al-
though the sensitivity of DLST is not enough, a posi-
tive result often contributes to the diagnosis of drug
induced hypersensitivity reaction.6 In this case, DLST
of SM was positive, but that of PZA, which has been
associated with dose-dependent pharmacological he-
patotoxicity, was negative.
Unfortunately, due to the patient’s poor condition
and old age, we could not perform bronchoalveolar
lavage or transbronchial lung biopsy. However, differ-
ential cell count of sputum did not show the increase
of eosinophils, suggesting that this case was not
eosinophilic pneumonia.7 Lung damage induced by
cytotoxic drugs is generally irreversible. 8 On the
other hand, interstitial pneumonia caused by immu-
nological drug reactions usually responds to steroid
therapy.9 Based on the good response to steroid ther-
apy, the increase of blood eosinophils, and the posi-
tive result of DLST, we diagnosed this case as allergic
drug induced pneumonitis due to SM.
Interstitial pneumonia induced by a drug is often
serious and can result in death without early diagno-
sis and management. Although SM-induced pneu-
monitis is extremely rare, we have to recognize that
this drug can cause such a life-threatening ADR.
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